CONMED Corporation (CNMD) Stock Competitors & Peer Comparison

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, CNMD is priced at $34.65, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, CNMD's ROE is +0.05%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, CNMD is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check BSX-PA's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ABT has a market cap of 152.8B. Regarding current trading prices, CNMD is priced at $34.65, while ABT trades at $87.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ABT's P/E ratio is 24.57. In terms of profitability, CNMD's ROE is +0.05%, compared to ABT's ROE of +0.12%. Regarding short-term risk, CNMD is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check ABT's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ISRG has a market cap of 146B. Regarding current trading prices, CNMD is priced at $34.65, while ISRG trades at $412.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ISRG's P/E ratio is 50.03. In terms of profitability, CNMD's ROE is +0.05%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, CNMD is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check ISRG's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SYK has a market cap of 114.8B. Regarding current trading prices, CNMD is priced at $34.65, while SYK trades at $299.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SYK's P/E ratio is 34.70. In terms of profitability, CNMD's ROE is +0.05%, compared to SYK's ROE of +0.15%. Regarding short-term risk, CNMD is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check SYK's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, MDT has a market cap of 95B. Regarding current trading prices, CNMD is priced at $34.65, while MDT trades at $73.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas MDT's P/E ratio is 20.67. In terms of profitability, CNMD's ROE is +0.05%, compared to MDT's ROE of +0.10%. Regarding short-term risk, CNMD is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check MDT's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BSX has a market cap of 71.3B. Regarding current trading prices, CNMD is priced at $34.65, while BSX trades at $47.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BSX's P/E ratio is 20.07. In terms of profitability, CNMD's ROE is +0.05%, compared to BSX's ROE of +0.15%. Regarding short-term risk, CNMD is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check BSX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BRKRP has a market cap of 65.7B. Regarding current trading prices, CNMD is priced at $34.65, while BRKRP trades at $434.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BRKRP's P/E ratio is N/A. In terms of profitability, CNMD's ROE is +0.05%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, CNMD is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check BRKRP's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, EW has a market cap of 50.8B. Regarding current trading prices, CNMD is priced at $34.65, while EW trades at $88.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas EW's P/E ratio is 47.66. In terms of profitability, CNMD's ROE is +0.05%, compared to EW's ROE of +0.11%. Regarding short-term risk, CNMD is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check EW's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, DXCM has a market cap of 28.9B. Regarding current trading prices, CNMD is priced at $34.65, while DXCM trades at $74.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas DXCM's P/E ratio is 32.13. In terms of profitability, CNMD's ROE is +0.05%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, CNMD is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check DXCM's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, RMD has a market cap of 27.1B. Regarding current trading prices, CNMD is priced at $34.65, while RMD trades at $186.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas RMD's P/E ratio is 17.99. In terms of profitability, CNMD's ROE is +0.05%, compared to RMD's ROE of +0.24%. Regarding short-term risk, CNMD is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check RMD's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, PHG has a market cap of 24.8B. Regarding current trading prices, CNMD is priced at $34.65, while PHG trades at $26.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas PHG's P/E ratio is 22.48. In terms of profitability, CNMD's ROE is +0.05%, compared to PHG's ROE of +0.09%. Regarding short-term risk, CNMD is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check PHG's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, STE has a market cap of 20.7B. Regarding current trading prices, CNMD is priced at $34.65, while STE trades at $211.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas STE's P/E ratio is 26.61. In terms of profitability, CNMD's ROE is +0.05%, compared to STE's ROE of +0.11%. Regarding short-term risk, CNMD is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check STE's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, CNMD is priced at $34.65, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ABMD's P/E ratio is 65.36. In terms of profitability, CNMD's ROE is +0.05%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, CNMD is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check ABMD's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ZBH has a market cap of 16B. Regarding current trading prices, CNMD is priced at $34.65, while ZBH trades at $82.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ZBH's P/E ratio is 21.49. In terms of profitability, CNMD's ROE is +0.05%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, CNMD is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check ZBH's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, CNMD is priced at $34.65, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SWAV's P/E ratio is 78.76. In terms of profitability, CNMD's ROE is +0.05%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, CNMD is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check SWAV's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, CNMD is priced at $34.65, while PEN trades at $318.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas PEN's P/E ratio is 73.67. In terms of profitability, CNMD's ROE is +0.05%, compared to PEN's ROE of +0.12%. Regarding short-term risk, CNMD is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check PEN's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SNN has a market cap of 12.5B. Regarding current trading prices, CNMD is priced at $34.65, while SNN trades at $29.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SNN's P/E ratio is 20.60. In terms of profitability, CNMD's ROE is +0.05%, compared to SNN's ROE of +0.12%. Regarding short-term risk, CNMD is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check SNN's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ALGN has a market cap of 12.2B. Regarding current trading prices, CNMD is priced at $34.65, while ALGN trades at $169.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ALGN's P/E ratio is 28.53. In terms of profitability, CNMD's ROE is +0.05%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, CNMD is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check ALGN's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, CNMD is priced at $34.65, while GMED trades at $79.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas GMED's P/E ratio is 18.64. In terms of profitability, CNMD's ROE is +0.05%, compared to GMED's ROE of +0.13%. Regarding short-term risk, CNMD is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check GMED's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, PODD has a market cap of 10.3B. Regarding current trading prices, CNMD is priced at $34.65, while PODD trades at $148.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas PODD's P/E ratio is 34.61. In terms of profitability, CNMD's ROE is +0.05%, compared to PODD's ROE of +0.21%. Regarding short-term risk, CNMD is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check PODD's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, CNMD is priced at $34.65, while MASI trades at $178.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas MASI's P/E ratio is 44.32. In terms of profitability, CNMD's ROE is +0.05%, compared to MASI's ROE of +0.09%. Regarding short-term risk, CNMD is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check MASI's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BRKR has a market cap of 8.9B. Regarding current trading prices, CNMD is priced at $34.65, while BRKR trades at $58.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BRKR's P/E ratio is -243.50. In terms of profitability, CNMD's ROE is +0.05%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, CNMD is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check BRKR's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BIO has a market cap of 8.3B. Regarding current trading prices, CNMD is priced at $34.65, while BIO trades at $305.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BIO's P/E ratio is 50.91. In terms of profitability, CNMD's ROE is +0.05%, compared to BIO's ROE of +0.02%. Regarding short-term risk, CNMD is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check BIO's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BIO-B has a market cap of 8.3B. Regarding current trading prices, CNMD is priced at $34.65, while BIO-B trades at $305.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BIO-B's P/E ratio is 50.72. In terms of profitability, CNMD's ROE is +0.05%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, CNMD is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check BIO-B's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, GKOS has a market cap of 6.1B. Regarding current trading prices, CNMD is priced at $34.65, while GKOS trades at $103.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas GKOS's P/E ratio is -31.25. In terms of profitability, CNMD's ROE is +0.05%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, CNMD is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check GKOS's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, CNMD is priced at $34.65, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas NARI's P/E ratio is -59.24. In terms of profitability, CNMD's ROE is +0.05%, compared to NARI's ROE of -0.00%. Regarding short-term risk, CNMD is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check NARI's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, LIVN has a market cap of 4.1B. Regarding current trading prices, CNMD is priced at $34.65, while LIVN trades at $73.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas LIVN's P/E ratio is 37.66. In terms of profitability, CNMD's ROE is +0.05%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, CNMD is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check LIVN's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, CNMD is priced at $34.65, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas AXNX's P/E ratio is -709.80. In terms of profitability, CNMD's ROE is +0.05%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, CNMD is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check AXNX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, CNMD is priced at $34.65, while IRTC trades at $109.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas IRTC's P/E ratio is -128.44. In terms of profitability, CNMD's ROE is +0.05%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, CNMD is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check IRTC's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, CNMD is priced at $34.65, while ITGR trades at $90.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ITGR's P/E ratio is 22.37. In terms of profitability, CNMD's ROE is +0.05%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, CNMD is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check ITGR's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, CNMD is priced at $34.65, while TMDX trades at $67.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas TMDX's P/E ratio is 15.45. In terms of profitability, CNMD's ROE is +0.05%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, CNMD is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check TMDX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, CNMD is priced at $34.65, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas NUVA's P/E ratio is 75.00. In terms of profitability, CNMD's ROE is +0.05%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, CNMD is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check NUVA's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, CNMD is priced at $34.65, while AXGN trades at $38.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas AXGN's P/E ratio is -60.50. In terms of profitability, CNMD's ROE is +0.05%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, CNMD is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check AXGN's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, CNMD is priced at $34.65, while ESTA trades at $68.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ESTA's P/E ratio is -46.31. In terms of profitability, CNMD's ROE is +0.05%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, CNMD is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check ESTA's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, CNMD is priced at $34.65, while UFPT trades at $218.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas UFPT's P/E ratio is 24.84. In terms of profitability, CNMD's ROE is +0.05%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, CNMD is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check UFPT's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, PRCT has a market cap of 1.6B. Regarding current trading prices, CNMD is priced at $34.65, while PRCT trades at $27.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas PRCT's P/E ratio is -15.22. In terms of profitability, CNMD's ROE is +0.05%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, CNMD is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check PRCT's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, CNMD is priced at $34.65, while AHCO trades at $9.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas AHCO's P/E ratio is -16.83. In terms of profitability, CNMD's ROE is +0.05%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, CNMD is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check AHCO's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, CNMD is priced at $34.65, while TNDM trades at $19.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas TNDM's P/E ratio is -13.96. In terms of profitability, CNMD's ROE is +0.05%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, CNMD is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check TNDM's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, CNMD is priced at $34.65, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas HSKA's P/E ratio is -62.49. In terms of profitability, CNMD's ROE is +0.05%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, CNMD is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check HSKA's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, CNMD is priced at $34.65, while ENOV trades at $21.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ENOV's P/E ratio is -1.09. In terms of profitability, CNMD's ROE is +0.05%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, CNMD is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check ENOV's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, CNMD is priced at $34.65, while IART trades at $15.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas IART's P/E ratio is -2.42. In terms of profitability, CNMD's ROE is +0.05%, compared to IART's ROE of -0.48%. Regarding short-term risk, CNMD is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check IART's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, CNMD is priced at $34.65, while BFLY trades at $4.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BFLY's P/E ratio is -15.38. In terms of profitability, CNMD's ROE is +0.05%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, CNMD is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check BFLY's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, CNMD is priced at $34.65, while INSP trades at $40.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas INSP's P/E ratio is 9.29. In terms of profitability, CNMD's ROE is +0.05%, compared to INSP's ROE of +0.18%. Regarding short-term risk, CNMD is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check INSP's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, CNMD is priced at $34.65, while IRMD trades at $92.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas IRMD's P/E ratio is 50.30. In terms of profitability, CNMD's ROE is +0.05%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, CNMD is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check IRMD's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, CNMD is priced at $34.65, while AVNS trades at $25.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas AVNS's P/E ratio is -15.67. In terms of profitability, CNMD's ROE is +0.05%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, CNMD is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check AVNS's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, CNMD is priced at $34.65, while ATEC trades at $7.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ATEC's P/E ratio is -9.01. In terms of profitability, CNMD's ROE is +0.05%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, CNMD is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check ATEC's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, CNMD is priced at $34.65, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SILK's P/E ratio is -18.96. In terms of profitability, CNMD's ROE is +0.05%, compared to SILK's ROE of -0.35%. Regarding short-term risk, CNMD is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check SILK's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, CNMD is priced at $34.65, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas FNA's P/E ratio is -19.83. In terms of profitability, CNMD's ROE is +0.05%, compared to FNA's ROE of -0.35%. Regarding short-term risk, CNMD is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check FNA's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, AORT has a market cap of 1B. Regarding current trading prices, CNMD is priced at $34.65, while AORT trades at $21.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas AORT's P/E ratio is 84.16. In terms of profitability, CNMD's ROE is +0.05%, compared to AORT's ROE of +0.03%. Regarding short-term risk, CNMD is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check AORT's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, INMD has a market cap of 861M. Regarding current trading prices, CNMD is priced at $34.65, while INMD trades at $13.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas INMD's P/E ratio is 10.07. In terms of profitability, CNMD's ROE is +0.05%, compared to INMD's ROE of +0.13%. Regarding short-term risk, CNMD is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check INMD's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, CNMD is priced at $34.65, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas CSII's P/E ratio is -20.83. In terms of profitability, CNMD's ROE is +0.05%, compared to CSII's ROE of -0.14%. Regarding short-term risk, CNMD is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check CSII's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SSII has a market cap of 788.5M. Regarding current trading prices, CNMD is priced at $34.65, while SSII trades at $3.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SSII's P/E ratio is -78.80. In terms of profitability, CNMD's ROE is +0.05%, compared to SSII's ROE of -0.23%. Regarding short-term risk, CNMD is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check SSII's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, CNMD is priced at $34.65, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas CRY's P/E ratio is 425.71. In terms of profitability, CNMD's ROE is +0.05%, compared to CRY's ROE of +0.03%. Regarding short-term risk, CNMD is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check CRY's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, LMRI has a market cap of 706.2M. Regarding current trading prices, CNMD is priced at $34.65, while LMRI trades at $7.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas LMRI's P/E ratio is -18.85. In terms of profitability, CNMD's ROE is +0.05%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, CNMD is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check LMRI's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, CBLL has a market cap of 668.2M. Regarding current trading prices, CNMD is priced at $34.65, while CBLL trades at $17.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas CBLL's P/E ratio is -10.87. In terms of profitability, CNMD's ROE is +0.05%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, CNMD is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check CBLL's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SIBN has a market cap of 615.1M. Regarding current trading prices, CNMD is priced at $34.65, while SIBN trades at $13.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SIBN's P/E ratio is -35.56. In terms of profitability, CNMD's ROE is +0.05%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, CNMD is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check SIBN's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, CNMD is priced at $34.65, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SRDX's P/E ratio is -34.66. In terms of profitability, CNMD's ROE is +0.05%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, CNMD is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check SRDX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BWAY has a market cap of 605.6M. Regarding current trading prices, CNMD is priced at $34.65, while BWAY trades at $15.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BWAY's P/E ratio is 70.18. In terms of profitability, CNMD's ROE is +0.05%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, CNMD is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check BWAY's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, CNMD is priced at $34.65, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas APEN's P/E ratio is -9.43. In terms of profitability, CNMD's ROE is +0.05%, compared to APEN's ROE of -0.85%. Regarding short-term risk, CNMD is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check APEN's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, CERS has a market cap of 569M. Regarding current trading prices, CNMD is priced at $34.65, while CERS trades at $2.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas CERS's P/E ratio is -56.80. In terms of profitability, CNMD's ROE is +0.05%, compared to CERS's ROE of -0.15%. Regarding short-term risk, CNMD is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check CERS's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, NPCE has a market cap of 562.9M. Regarding current trading prices, CNMD is priced at $34.65, while NPCE trades at $16.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas NPCE's P/E ratio is -25.40. In terms of profitability, CNMD's ROE is +0.05%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, CNMD is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check NPCE's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, CTKB has a market cap of 547.6M. Regarding current trading prices, CNMD is priced at $34.65, while CTKB trades at $4.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas CTKB's P/E ratio is -7.31. In terms of profitability, CNMD's ROE is +0.05%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, CNMD is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check CTKB's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, TCMD has a market cap of 540.9M. Regarding current trading prices, CNMD is priced at $34.65, while TCMD trades at $23.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas TCMD's P/E ratio is 27.56. In terms of profitability, CNMD's ROE is +0.05%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, CNMD is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check TCMD's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BVS has a market cap of 537.2M. Regarding current trading prices, CNMD is priced at $34.65, while BVS trades at $7.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BVS's P/E ratio is 19.34. In terms of profitability, CNMD's ROE is +0.05%, compared to BVS's ROE of +0.16%. Regarding short-term risk, CNMD is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check BVS's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, CNMD is priced at $34.65, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, CNMD's ROE is +0.05%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, CNMD is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check ZIMV's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, PACB has a market cap of 490.8M. Regarding current trading prices, CNMD is priced at $34.65, while PACB trades at $1.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas PACB's P/E ratio is -3.85. In terms of profitability, CNMD's ROE is +0.05%, compared to PACB's ROE of -4.88%. Regarding short-term risk, CNMD is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check PACB's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, LAB has a market cap of 448.9M. Regarding current trading prices, CNMD is priced at $34.65, while LAB trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas LAB's P/E ratio is -8.85. In terms of profitability, CNMD's ROE is +0.05%, compared to LAB's ROE of -0.21%. Regarding short-term risk, CNMD is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check LAB's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, KIDS has a market cap of 427.7M. Regarding current trading prices, CNMD is priced at $34.65, while KIDS trades at $16.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas KIDS's P/E ratio is -9.91. In terms of profitability, CNMD's ROE is +0.05%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, CNMD is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check KIDS's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, VREX has a market cap of 422.3M. Regarding current trading prices, CNMD is priced at $34.65, while VREX trades at $10.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas VREX's P/E ratio is -5.01. In terms of profitability, CNMD's ROE is +0.05%, compared to VREX's ROE of -0.18%. Regarding short-term risk, CNMD is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check VREX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, CLPT has a market cap of 379.1M. Regarding current trading prices, CNMD is priced at $34.65, while CLPT trades at $12.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas CLPT's P/E ratio is -12.64. In terms of profitability, CNMD's ROE is +0.05%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, CNMD is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check CLPT's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, OFIX has a market cap of 374.7M. Regarding current trading prices, CNMD is priced at $34.65, while OFIX trades at $9.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas OFIX's P/E ratio is -6.18. In terms of profitability, CNMD's ROE is +0.05%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, CNMD is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check OFIX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, VMD has a market cap of 372.6M. Regarding current trading prices, CNMD is priced at $34.65, while VMD trades at $9.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas VMD's P/E ratio is 26.27. In terms of profitability, CNMD's ROE is +0.05%, compared to VMD's ROE of +0.11%. Regarding short-term risk, CNMD is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check VMD's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, DCTH has a market cap of 365.9M. Regarding current trading prices, CNMD is priced at $34.65, while DCTH trades at $10.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas DCTH's P/E ratio is 1060.00. In terms of profitability, CNMD's ROE is +0.05%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, CNMD is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check DCTH's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, AVR has a market cap of 334.8M. Regarding current trading prices, CNMD is priced at $34.65, while AVR trades at $9.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas AVR's P/E ratio is -4.10. In terms of profitability, CNMD's ROE is +0.05%, compared to AVR's ROE of -1.24%. Regarding short-term risk, CNMD is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check AVR's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, MASS has a market cap of 326.3M. Regarding current trading prices, CNMD is priced at $34.65, while MASS trades at $8.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas MASS's P/E ratio is -8.90. In terms of profitability, CNMD's ROE is +0.05%, compared to MASS's ROE of -0.26%. Regarding short-term risk, CNMD is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check MASS's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, CNMD is priced at $34.65, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SMLR's P/E ratio is 3.92. In terms of profitability, CNMD's ROE is +0.05%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, CNMD is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check SMLR's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ELMD has a market cap of 304.8M. Regarding current trading prices, CNMD is priced at $34.65, while ELMD trades at $36.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ELMD's P/E ratio is 31.46. In terms of profitability, CNMD's ROE is +0.05%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, CNMD is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check ELMD's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SENS has a market cap of 285.7M. Regarding current trading prices, CNMD is priced at $34.65, while SENS trades at $6.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SENS's P/E ratio is -3.47. In terms of profitability, CNMD's ROE is +0.05%, compared to SENS's ROE of -1.30%. Regarding short-term risk, CNMD is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check SENS's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, CATX has a market cap of 282.7M. Regarding current trading prices, CNMD is priced at $34.65, while CATX trades at $3.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas CATX's P/E ratio is -2.60. In terms of profitability, CNMD's ROE is +0.05%, compared to CATX's ROE of -0.42%. Regarding short-term risk, CNMD is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check CATX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, PMI has a market cap of 266.8M. Regarding current trading prices, CNMD is priced at $34.65, while PMI trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas PMI's P/E ratio is -0.22. In terms of profitability, CNMD's ROE is +0.05%, compared to PMI's ROE of +4.99%. Regarding short-term risk, CNMD is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check PMI's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SGHT has a market cap of 247M. Regarding current trading prices, CNMD is priced at $34.65, while SGHT trades at $4.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SGHT's P/E ratio is -6.49. In terms of profitability, CNMD's ROE is +0.05%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, CNMD is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check SGHT's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, CNMD is priced at $34.65, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas MGRM's P/E ratio is -11.11. In terms of profitability, CNMD's ROE is +0.05%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, CNMD is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check MGRM's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, TMCI has a market cap of 233.5M. Regarding current trading prices, CNMD is priced at $34.65, while TMCI trades at $3.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas TMCI's P/E ratio is -3.75. In terms of profitability, CNMD's ROE is +0.05%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, CNMD is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check TMCI's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, CNMD is priced at $34.65, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas NVRO's P/E ratio is -1.91. In terms of profitability, CNMD's ROE is +0.05%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, CNMD is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check NVRO's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, RXST has a market cap of 216.9M. Regarding current trading prices, CNMD is priced at $34.65, while RXST trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas RXST's P/E ratio is -4.64. In terms of profitability, CNMD's ROE is +0.05%, compared to RXST's ROE of -0.17%. Regarding short-term risk, CNMD is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check RXST's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, CNMD is priced at $34.65, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas EYES's P/E ratio is N/A. In terms of profitability, CNMD's ROE is +0.05%, compared to EYES's ROE of -2.64%. Regarding short-term risk, CNMD is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check EYES's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, PROF has a market cap of 201.8M. Regarding current trading prices, CNMD is priced at $34.65, while PROF trades at $6.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas PROF's P/E ratio is -5.38. In terms of profitability, CNMD's ROE is +0.05%, compared to PROF's ROE of -0.71%. Regarding short-term risk, CNMD is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check PROF's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, ANIK has a market cap of 194.7M. Regarding current trading prices, CNMD is priced at $34.65, while ANIK trades at $14.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas ANIK's P/E ratio is -18.52. In terms of profitability, CNMD's ROE is +0.05%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, CNMD is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check ANIK's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, CNMD is priced at $34.65, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas BSGM's P/E ratio is -5.81. In terms of profitability, CNMD's ROE is +0.05%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, CNMD is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check BSGM's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, CNMD is priced at $34.65, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas MDGS's P/E ratio is -0.27. In terms of profitability, CNMD's ROE is +0.05%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, CNMD is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check MDGS's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, APYX has a market cap of 165.8M. Regarding current trading prices, CNMD is priced at $34.65, while APYX trades at $3.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas APYX's P/E ratio is -18.00. In terms of profitability, CNMD's ROE is +0.05%, compared to APYX's ROE of -0.91%. Regarding short-term risk, CNMD is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check APYX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, INGN has a market cap of 164.9M. Regarding current trading prices, CNMD is priced at $34.65, while INGN trades at $6.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas INGN's P/E ratio is -6.69. In terms of profitability, CNMD's ROE is +0.05%, compared to INGN's ROE of -0.13%. Regarding short-term risk, CNMD is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check INGN's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, QTRX has a market cap of 164.9M. Regarding current trading prices, CNMD is priced at $34.65, while QTRX trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas QTRX's P/E ratio is -1.49. In terms of profitability, CNMD's ROE is +0.05%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, CNMD is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check QTRX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, CNMD is priced at $34.65, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas QIPT's P/E ratio is -15.87. In terms of profitability, CNMD's ROE is +0.05%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, CNMD is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check QIPT's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, EDAP has a market cap of 161.9M. Regarding current trading prices, CNMD is priced at $34.65, while EDAP trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas EDAP's P/E ratio is -5.27. In terms of profitability, CNMD's ROE is +0.05%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, CNMD is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for CNMD.Check EDAP's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, CVRX has a market cap of 144.1M. Regarding current trading prices, CNMD is priced at $34.65, while CVRX trades at $5.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas CVRX's P/E ratio is -2.70. In terms of profitability, CNMD's ROE is +0.05%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, CNMD is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check CVRX's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, TLSI has a market cap of 139.1M. Regarding current trading prices, CNMD is priced at $34.65, while TLSI trades at $3.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas TLSI's P/E ratio is -2.58. In terms of profitability, CNMD's ROE is +0.05%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, CNMD is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check TLSI's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, SNWV has a market cap of 136.3M. Regarding current trading prices, CNMD is priced at $34.65, while SNWV trades at $15.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas SNWV's P/E ratio is 16.51. In terms of profitability, CNMD's ROE is +0.05%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, CNMD is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check SNWV's competition here

CNMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNMD stands at 1B. In comparison, NNOX has a market cap of 135.7M. Regarding current trading prices, CNMD is priced at $34.65, while NNOX trades at $1.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNMD currently has a P/E ratio of 19.57, whereas NNOX's P/E ratio is -1.68. In terms of profitability, CNMD's ROE is +0.05%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, CNMD is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for CNMD.Check NNOX's competition here